Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting - Implications of the barriers between blood and brain

被引:179
作者
de Lange, ECM [1 ]
Danhof, M [1 ]
机构
[1] Leiden Amsterdam Ctr Drug Res, Div Pharmacol, Leiden, Netherlands
关键词
D O I
10.2165/00003088-200241100-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the clinical setting, drug concentrations in cerebrospinal fluid (CSF) are sometimes used as a surrogate for drug concentrations at the target site within the brain. However, the brain consists of multiple compartments and many factors are involved in the transport of drugs from plasma into the brain and the distribution within the brain. In particular, active transport processes at the level of the blood-brain barrier and blood-CSF barrier, such as those mediated by P-glycoprotein, may lead to complex relationships between concentrations in plasma, Ventricular and lumbar CSF, and other brain compartments. Therefore, CSF concentrations may be difficult to interpret and may have limited value. Pharmacokinetic data obtained by intracerebral microdialysis monitoring may be used instead, providing more valuable information. As non-invasive alternative techniques, positron emission tomography or magnetic resonance spectroscopy may be of added value.
引用
收藏
页码:691 / 703
页数:13
相关论文
共 139 条
[1]  
ABOTT NJ, 1991, CEREBROVAS BRAIN MET, V3, P39
[2]   PERMEABILITY OF THE BLOOD-BRAIN-BARRIER FOR ATENOLOL STUDIED BY POSITRON EMISSION TOMOGRAPHY [J].
AGON, P ;
GOETHALS, P ;
VANHAVER, D ;
KAUFMAN, JM .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1991, 43 (08) :597-600
[3]   A STUDY OF INTRATHECAL, CEREBROSPINAL FLUID-TO-BRAIN EXCHANGE [J].
AIRD, RB .
EXPERIMENTAL NEUROLOGY, 1984, 86 (02) :342-358
[4]   The choroid plexus epithelium is the site of the organic anion transport protein in the brain [J].
Angeletti, RH ;
Novikoff, PM ;
Juvvadi, SR ;
Fritschy, JM ;
Meier, PJ ;
Wolkoff, AW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (01) :283-286
[5]   Cerebrospinal fluid production is normal in Down syndrome [J].
Atack, JR ;
Rapoport, SI ;
Schapiro, MB .
NEUROBIOLOGY OF AGING, 1998, 19 (04) :307-309
[6]  
Baker SD, 1996, CANCER CHEMOTH PHARM, V37, P195
[7]   Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration [J].
Balis, FM ;
Blaney, SM ;
McCully, CL ;
Bacher, JD ;
Murphy, RF ;
Poplack, DG .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (03) :259-264
[8]   Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders [J].
Banks, WA .
JOURNAL OF NEUROVIROLOGY, 1999, 5 (06) :538-555
[9]   F-19 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY OF NEUROLEPTICS - THE 1ST INVIVO PHARMACOKINETICS OF TRIFLUOPERAZINE IN THE RAT-BRAIN AND THE 1ST INVIVO SPECTRUM OF FLUPHENAZINE IN THE HUMAN BRAIN [J].
BARTELS, M ;
GUNTHER, U ;
ALBERT, K ;
MANN, K ;
SCHUFF, N ;
STUCKSTEDTE, H .
BIOLOGICAL PSYCHIATRY, 1991, 30 (07) :656-662
[10]   PHARMACOKINETICS OF LAMIVUDINE AND BCH-189 IN PLASMA AND CEREBROSPINAL-FLUID OF NONHUMAN-PRIMATES [J].
BLANEY, SM ;
DANIEL, MJ ;
HARKER, AJ ;
GODWIN, K ;
BALIS, FM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2779-2782